Taysha Gene Therapies, Inc.

Equities

TSHA

US8776191061

Biotechnology & Medical Research

Real-time Estimate Cboe BZX 03:00:32 2024-03-28 pm EDT 5-day change 1st Jan Change
2.895 USD -8.68% Intraday chart for Taysha Gene Therapies, Inc. -7.42% +62.15%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Chardan Adjusts PT on Taysha Gene Therapies to $7 From $5 as Gene Therapy for Rett Syndrome Shows 'Sustained Benefit', Keeps Buy Rating MT
Wall Street Set to Open Flat as Investors Look Toward Fed Decision; Oil Prices Drop Sharply MT
US Futures Flat in Wednesday's Premarket as Investors Await Fed's Interest Rate Decision MT
Top Premarket Gainers MT
Needham Adjusts Taysha Gene Therapies Price Target to $7 From $5, Maintains Buy Rating MT
Taysha Gene Therapies Surges 26% Premarket After Full-Year 2023 Results Show Narrowing Net Loss, Surging Revenue MT
North American Morning Briefing : Markets on Hold as Fed Decision Nears DJ
Transcript : Taysha Gene Therapies, Inc., 2023 Earnings Call, Mar 19, 2024
Taysha Gene Therapies, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Taysha Gene Therapies, Inc. Announces First Pediatric Patient Dosed with TSHA-102 in REVEAL Phase 1/2 Pediatric Trial in Rett Syndrome CI
Taysha Gene Therapies, Inc.(NasdaqGS:TSHA) added to NASDAQ Biotechnology Index CI
Taysha Gene Therapies Gets Expanded Eligibility in Canada for Early Trial of Rett Syndrome Treatment MT
Taysha Gene Therapies, Inc. Announces Expanded Eligibility in REVEAL Phase 1/2 Adult Trial to Include Adolescent Rett Syndrome Patients CI
Taysha Gene Therapies Insider Bought Shares Worth $163,000, According to a Recent SEC Filing MT
Cantor Fitzgerald Adjusts Price Target on Taysha Gene Therapies to $7 From $6, Keeps Overweight Rating MT
Taysha Gene Therapies Q3 Net Loss Widens Unexpectedly MT
Transcript : Taysha Gene Therapies, Inc., Q3 2023 Earnings Call, Nov 14, 2023
Earnings Flash (TSHA) TAYSHA GENE THERAPIES Posts Q3 Revenue $4.75M MT
Taysha Gene Therapies, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Taysha Gene Therapies, Inc. announced that it expects to receive $40 million in funding CI
Taysha Gene Therapies, Inc. Appoints Alison Long to Board and Committees CI
Sector Update: Health Care Stocks Mixed in Afternoon Trading MT
Taysha Gene Says New Preclinical Data Reinforce TSHA-102 Potential to Address Rett Syndrome Root Cause; Shares Rise MT
Taysha Gene Therapies Presents New Preclinical In-vitro Data on TSHA-102 in Rett Syndrome Supporting miRARE Regulation of MECP2 Expression at the European Society of Gene & Cell Therapy 30th Annual Congress CI
Pliant Therapeutics Appoints Chief Regulatory Officer MT
Chart Taysha Gene Therapies, Inc.
More charts
Taysha Gene Therapies Inc is a clinical-stage biotechnology company, which is focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system. The Company’s lead clinical program, TSHA-102, is in development for the treatment of Rett syndrome, a rare neurodevelopmental disorder. The Company is evaluating TSHA-102 in the REVEALPhase I/II adolescent and adult clinical trial, which is a first-in-human, open-label, randomized, dose escalation and dose-expansion, multicenter study evaluating the safety and preliminary efficacy of TSHA-102 in female patients aged 12-years and older with Rett syndrome. It has acquired a worldwide right to a clinical-stage, intrathecally dosed AAV9 gene therapy program, TSHA-120, for the treatment of giant axonal neuropathy (GAN). It received orphan drug designation from the European Commission for TSHA-120 for the treatment of GAN.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
3.17 USD
Average target price
6.056 USD
Spread / Average Target
+91.03%
Consensus
  1. Stock
  2. Equities
  3. Stock Taysha Gene Therapies, Inc. - Nasdaq
  4. News Taysha Gene Therapies, Inc.
  5. Taysha Gene Therapies : Teams Up With Yale Researchers to Develop Gene Therapy for Neurodevelopmental Disorders